CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth

Financial Performance - CRISPR Therapeutics reported total revenue of $116 million for FY2025, with $54 million generated in Q4 alone, driven by a nearly threefold increase in patient initiations compared to the previous year [1][6] - A total of 147 patients have started treatment for sickle cell disease or beta thalassemia, supported by expanded reimbursement access across the US, Europe, and the Middle East [1] Product Development - The company is advancing a diverse 'in vivo' liver editing portfolio using lipid nanoparticles, with key programs including CTX310 for cardiovascular conditions and CTX460 for alpha-1 antitrypsin deficiency, expected to enter clinical trials in mid-2026 [2] - CRISPR is collaborating with Sirius Therapeutics on siRNA-based programs targeting thromboembolic diseases, with Phase 2 data for their lead Factor XI candidate expected in H2 2026 [3] - The clinical pipeline includes 'zugo-cel,' a CAR-T cell therapy for autoimmune diseases and B-cell cancers, and CTX213, an islet cell replacement candidate for Type 1 diabetes showing promising preclinical efficacy [3] Technology and Innovation - CRISPR Therapeutics utilizes its Cas9 platform to develop gene-based medicines for serious human diseases [4]